DP
Diadema Partners Portfolio holdings
AUM
$161M
This Quarter Return
-0.06%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$125M
AUM Growth
+$125M
(+41%)
Cap. Flow
+$38M
Cap. Flow
% of AUM
30.38%
Top 10 Holdings %
Top 10 Hldgs %
68.21%
Holding
117
New
20
Increased
17
Reduced
6
Closed
31
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$18.9M |
| 2 |
Eli Lilly
LLY
|
$15.9M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$9M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.88M |
| 5 |
argenx
ARGX
|
$6.78M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$9.05M |
| 2 |
AbbVie
ABBV
|
$8.89M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$6.68M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$5.6M |
| 5 |
AstraZeneca
AZN
|
$3.93M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Trevi Therapeutics
TRVI
$885M
| $1.13M | 0.3% |
+180,000
| New | +$1.13M |
|
27
Relay Therapeutics
RLAY
$631M
| $1.12M | 0.29% |
426,346
-79,432
| -16% | -$208K |
|
28
Pacira BioSciences
PCRX
$1.22B
| $967K | 0.25% |
+38,926
| New | +$967K |
|
29
UroGen Pharma
URGN
$904M
| $843K | 0.22% |
76,220
+26,220
| +52% | +$290K |
|
|
CLYM
30
Climb Bio, Inc. Common Stock
CLYM
$151M
| $817K | 0.21% |
669,803
+295,380
| +79% | +$360K |
|
31
Cytokinetics
CYTK
$5.94B
| $804K | 0.21% |
+20,000
| New | +$804K |
|
32
Replimune Group
REPL
$461M
| $727K | 0.19% |
74,530
-39,470
| -35% | -$385K |
|
33
Reviva Pharmaceuticals
RVPH
$30.8M
| $621K | 0.16% |
+650,723
| New | +$621K |
|
34
Alector
ALEC
$262M
| $562K | 0.15% |
456,546
+217,527
| +91% | +$268K |
|
35
uniQure
QURE
$933M
| $387K | 0.1% |
+36,500
| New | +$387K |
|
36
Olema Pharmaceuticals
OLMA
$444M
| $376K | 0.1% |
+100,000
| New | +$376K |
|
37
Gossamer Bio
GOSS
$589M
| $297K | 0.08% |
269,589
+51,602
| +24% | +$56.8K |
|
38
ProQR Therapeutics
PRQR
$241M
| $276K | 0.07% |
207,694
+49,671
| +31% | +$66.1K |
|
39
Eledon Pharmaceuticals
ELDN
$153M
| $219K | 0.06% |
64,613
-11,181
| -15% | -$37.9K |
|
|
MREO
40
Mereo BioPharma
MREO
$281M
| $169K | 0.04% |
+492,215
| New | +$169K |
|
41
Terns Pharmaceuticals
TERN
$662M
| $155K | 0.04% |
56,098
+5,728
| +11% | +$15.8K |
|
42
Sagimet Biosciences
SGMT
$239M
| $150K | 0.04% |
+46,019
| New | +$150K |
|
43
Candel Therapeutics
CADL
$322M
| $142K | 0.04% |
25,045
+5,045
| +25% | +$28.5K |
|
|
44
AbbVie
ABBV
$374B
| – | – |
-50,000
| Closed | -$8.89M |
|
45
Arcellx
ACLX
$3.87B
| – | – |
-10,100
| Closed | -$775K |
|
46
Agios Pharmaceuticals
AGIO
$2.28B
| – | – |
0
| – | – |
|
47
Altimmune
ALT
$331M
| – | – |
0
| – | – |
|
48
ALX Oncology
ALXO
$55.2M
| – | – |
-197,680
| Closed | -$330K |
|
49
Amgen
AMGN
$154B
| – | – |
0
| – | – |
|
50
AnaptysBio
ANAB
$577M
| – | – |
0
| – | – |
|